Sign inJoin waitlistJoin the waitlist

MD

Matthew Dallos

Assistant Attending Physician · New York Presbyterian Hospital

Credentials: · · · · ·

History

Memorial Hospital for Cancer and allied Diseases
2023–Present

Hematology and Medical Oncology
Columbia University
2015–2018
Internal Medicine
NYU Grossman School of Medicine
2012–2015
Northwestern University Feinberg School of Medicine
2008–2012

Research

Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Clinical Cancer Research · 2021 · 109 citations
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Clinical Cancer Research · 2020 · Co-first of 19 authors · 107 citations
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
Cell Reports Medicine · 2023 · 81 citations

CD
Charles Drake
11 papers
Aleksandar Obradovic
8 papers · 6 as a resident
Patrick McCann
7 papers
Catherine Spina
5 papers · 1 as a resident
HS
Howard Scher
5 papers
Karie Runcie
4 papers
Mark Stein
4 papers
Renu Virk
4 papers
CG
Christopher Gaffney
3 papers · 1 as a fellow
David Aggen
3 papers
Emmanuel Antonarakis
3 papers
Guarionex DeCastro
3 papers

Clinical trials

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2024–2029
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Principal investigator · Active not recruiting · Phase 2, Phase 3
Columbia University
2019–2023
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Principal investigator · Active not recruiting · Phase 2
Columbia University
2018–2022
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2018–2027